Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 15/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648354 | 1.00 | AADAT (0.42) | AADATCPT2CPT1ACPT1BNPC1 | |
| SCHEMBL20489413 | 0.78 | AADAT (0.52) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL20489411 | 0.78 | AADAT (0.52) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL475512 | 0.77 | TRPV1 (0.46) | CPT2CPT1ACPT1BRAB9ASMN1; SMN2 | |
| SCHEMBL5645605 | 0.77 | TRPV1 (0.46) | CPT2CPT1ACPT1BRAB9ASMN1; SMN2 | |
| SCHEMBL20489459 | 0.74 | AADAT (0.73) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL20489456 | 0.74 | AADAT (0.73) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL22705489 | 0.74 | LMNA (0.47) | AADATCPT2CPT1ASMN1; SMN2 | |
| SCHEMBL27798798 | 0.72 | CPT1A (0.47) | CPT2CPT1ACPT1BRAB9ASMN1; SMN2 | |
| SCHEMBL2724717 | 0.72 | NPC1 (0.37) | AADATCPT2CPT1ACPT1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | AADAT 3761/4885CPT2 4011/4885CPT1A 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.